BIRC3 and cancer: Although IAPs are collectively referred to as pro-oncogenic, the literature regarding BIRC3 (cIAP2) is conflicted; multiple clinical studies have demonstrated an unfavorable contribution of BIRC3 inactivation in cancer patients [35].